| Type | Title | Date Released | |
|---|---|---|---|
10-Q | Form 10-Q New | ||
8-K | Perspective Therapeutics Reports Q3 2026 Results and Provides Business Updates New | ||
8-K | Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from Phase 1/2a Study in Advanced Melanoma at SITC 2026 | ||
8-K | Perspective Therapeutics Presents Encouraging Data from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan in Advanced NETs | ||
8-K | Perspective Therapeutics Announces Positive Interim Phase 1/2a Results for [²¹²Pb]VMT-α-NET in Advanced NETs | ||
8-K | Perspective Therapeutics Granted Fast Track Designation for [212Pb]PSV359 in Advanced Solitary Fibrous Tumors | ||
8-K | Perspective Therapeutics Highlights Next-Generation Radiopharmaceuticals Portfolio and Upcoming 2026 Data | ||
SCHEDULE 13D/A | Lantheus Holdings, Inc. (Filed by) | ||
8-K | Perspective Therapeutics Announces Clinical Collaboration and Supply Agreement with Merck to Evaluate [212Pb]PSV359 in Combination with Keytruda® in FAP-α Posit | ||
8-K | Perspective Therapeutics Highlights Next-Generation Radiopharmaceuticals Pipeline and Clinical Progress | ||
4 | Lantheus Holdings, Inc. (Reporting) | ||
4 | Lantheus Holdings, Inc. (Reporting) |